Recent cancer studies have revealed that aberrant expression or hyperactivity of B4GALT1 can reshape the glycosylation landscape of tumor cells, driving oncogenic phenotypes such as increased invasiveness, metastasis, and immune evasion (Chen et al., 2023; Cui et al., 2023). The gene discussed is B4GALT1; the disease is cancer.